SALLY SUSMAN - 27 Feb 2025 Form 4 Insider Report for PFIZER INC (PFE)

Role
Executive Vice President
Signature
/s/ Shanice A. Reid, by power of atty, for Sally Susman
Issuer symbol
PFE
Transactions as of
27 Feb 2025
Transactions value $
$531,162
Form type
4
Filing time
03 Mar 2025, 17:38:46 UTC
Previous filing
25 Feb 2025
Next filing
06 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PFE Common Stock Options Exercise $2,667,048 +85,182 +51.4% $31.31 250,866 27 Feb 2025 Direct F1
transaction PFE Common Stock Tax liability $-56,846 -2,178 -0.87% $26.10 248,688 27 Feb 2025 Direct F2
transaction PFE Common Stock Tax liability $-2,079,041 -79,779 -32.1% $26.06 168,909 27 Feb 2025 Direct F3, F4
holding PFE Common Stock 866 27 Feb 2025 By Rule 16b-3 Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PFE Stock Appreciation Rights Options Exercise $0 -85,182 -100% $0.000000 0 27 Feb 2025 Common Stock 85,182 $31.31 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F4 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.